Xuhang Zhu
Overview
Explore the profile of Xuhang Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu X, Liu H, He J, Hu C, Xie W, Luo B, et al.
Sci Rep
. 2025 Mar;
15(1):7257.
PMID: 40025116
Thyroid cancer treatments often impact patients' quality of life (QOL). The transoral endoscopic thyroidectomy vestibular approach (TOETVA) gets lot attention as a scarless alternative, but its influence on postoperative QOL...
2.
Yu X, Zhu X, Zhang L, Qin J, Feng C, Li Q
Front Pharmacol
. 2022 Jun;
13:883581.
PMID: 35645805
Aberrant activation of platelet-derived growth factor receptor α (PDGFRA) has been implicated in tumorigenesis and radioiodine resistance of thyroid cancer, indicating its therapeutic potential. In the present study, we confirmed...
3.
Wang Y, Miao X, Jiang Y, Wu Z, Zhu X, Liu H, et al.
Cell Death Dis
. 2022 Feb;
13(2):146.
PMID: 35165269
Hepatocellular carcinoma (HCC) still ranks among the top cancers worldwide with high incidence and mortality. Due to abnormal activation of the PI3K/AKT/mTOR signalling pathway in HCC, targeting this pathway represents...
4.
Miao X, Liu C, Jiang Y, Wang Y, Kong D, Wu Z, et al.
Cell Death Dis
. 2021 Oct;
12(11):1020.
PMID: 34716294
Intrahepatic cholangiocarcinoma (ICC), the second most common primary liver cancer, is a fatal malignancy with a poor prognosis and only very limited therapeutic options. Although molecular targeted therapy is emerged...
5.
Lan X, Cao J, Ye K, Zhang C, Zhang Q, Ge X, et al.
J Clin Endocrinol Metab
. 2020 Jul;
105(9).
PMID: 32674137
Context: Malignant thyroid tumor with distant metastasis is associated with poor outcome. Early detection of distant metastasis is of great clinical importance. Objective: Thyroid tumor infiltrated with T cells can...
6.
Lan X, Bao H, Ge X, Cao J, Fan X, Zhang Q, et al.
Cancer Sci
. 2020 Mar;
111(6):2163-2173.
PMID: 32187423
Papillary thyroid carcinoma (PTC) is the most common malignancy of the thyroid gland, with a relatively high cure rate. Distant metastasis (DM) of PTC is uncommon, but when it occurs,...
7.
Qian Y, Pan Z, Guo Z, Ge X, Zheng G, Cao J, et al.
Biomed Res Int
. 2019 Dec;
2019:1791065.
PMID: 31828091
Objectives: Many patients with papillary thyroid cancer (PTC) have a high recurrence risk and poor prognosis, and the main obstacle to the clinical diagnosis and treatment of PTC is lack...
8.
Lan X, Xu J, Chen C, Zheng C, Wang J, Cao J, et al.
Cell Physiol Biochem
. 2018 May;
47(3):1122-1132.
PMID: 29847813
Background/aims: Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. However, the molecular mechanisms responsible for its tumorigenesis and progression remain largely unknown. Circular RNA (circRNA) is...
9.
Lan X, Cao J, Xu J, Chen C, Zheng C, Wang J, et al.
J Clin Lab Anal
. 2018 May;
32(8):e22573.
PMID: 29790216
Background: Circular RNA (circRNA) is a new type of noncoding RNA that can serve as ideal biomarkers. Evidence has showed that circRNAs play an important role in carcinogenesis and cancer...
10.
Zhu X, Yu B, Huang Y, Zhou J, Ge M
Int J Endocrinol
. 2017 Mar;
2017:5702716.
PMID: 28356910
Papillary thyroid cancer (PTC) exhibits a higher incidence in women. Due to various ages at menarche and menopause, estrogen levels vary, which may account for the differences in the occurrence,...